Drug targeting to the colon with lectins and neoglycoconjugates

Advanced Drug Delivery Reviews

Volumn 56, Issue 4, 2004, Pages 491-509

  Minko, Tamara ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Colon cancer; Liposomes; Polymers; Prodrug; Review; Targeted drug delivery

Indexed keywords

BIOLOGICAL ORGANS; CELLS; TISSUE; TUMORS;

DRUG DELIVERY SYSTEMS (DDS);

DRUG PRODUCTS;

BETA GALACTOSIDE; CHITOSAN; DOXORUBICIN; DRUG CARRIER; EUDRAGIT; GALECTIN 3; GLYCOCONJUGATE; GLYCOLIPID; GLYCOPROTEIN; GUAR GUM; HORSERADISH PEROXIDASE; HYALURONIC ACID; INDOLEACETIC ACID; INDOMETACIN; LECTIN; LIPOSOME; MESALAZINE; MUCIN 2; PACLITAXEL; PADGEM PROTEIN; PRODRUG; SALAZOSULFAPYRIDINE; WHEAT GERM AGGLUTININ; XANTHAN;

ANTIGEN PRESENTING CELL; CELL ACTIVITY; CELL MATURATION; COLON; COLON CARCINOMA; CROHN DISEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; EXTRACELLULAR MATRIX; FILM COATING; GLYCOCALYX; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SMALL INTESTINE; STOMACH ACID; STOMACH PH; ULCERATIVE COLITIS;

EID: 1142273203     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.10.017     Document Type: Article

References (101)

1. Kopecek J., Kopeckova P., Minko T., Lu Z.-R., Peterson C.M. Water soluble polymers in tumor targeted delivery. J. Control. Release. 74:2001;147-158.
2. Dharap S.S., Qiu B., Williams G., Sinko P., Stein S., Minko T., Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J. Control. Rel. 91:2003;61-73.
3. Torchilin V.P., Lukyanov A.N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today. 8:2003;259-266.
4. Torchilin V.P. Drug targeting. Eur. J. Pharm. Sci. 11:(Suppl. 2):2000;S81-S91.
5. Kinget R., Kalala W., Vervoort L., van den Mooter G. Colonic drug targeting. J. Drug Targeting. 6:1998;129-149.
6. Bode H., Brendel E., Ahr G., Fuhr U., Harder S., Staib A.H. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur. J. Clin. Pharmacol. 50:1996;195-201.
7. Ishibashi T., Hatano H., Kobayashi M., Mizobe M., Yoshino H. In vivo drug release behavior in dogs from a new colon targeted delivery system. J. Control. Release. 57:1999;45-53.
8. Ishibashi T., Ikegami K., Kubo H., Kobayashi M., Mizobe M., Yoshino H. Evaluation of colonic absorbability of drugs in dogs using a novel colon targeted delivery capsule (CTDC). J. Control. Release. 59:1999;361-376.
9. Kramer W.G. Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. J. Clin. Pharmacol. 34:1994;1218-1221.
10. Semde R., Amighi K., Devleeschouwer M.J., Moes A.J. Studies of pectin HM/Eudragit RL/Eudragit NE film-coating formulations intended for colonic drug delivery. Int. J. Pharm. 197:2000;181-192.
11. Herrera-Ruiz D., Wang Q., Gudmundsson O.S., Cook T.J., Smith R.L., Faria T.N., Knipp G.T. Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues. AAPS Pharm. Sci. 3:2001;E9.
12. Shen H., Smith D.E., Brosius F.C. III. Developmental expression of PEPT1 and PEPT2 in rat small intestine, colon, and kidney. Pediatr. Res. 49:2001;789-795.
13. Wilding I.R., Davis S.S., O'Hagan D.T. Targeting of drugs and vaccines to the gut. Pharmacol. Ther. 62:1994;97-124.
14. Ziv E., Bendayan M. Intestinal absorption of peptides through the enterocytes. Microsc. Res. Tech. 49:2000;346-352.
15. Digenis G.A., Sandefer E. Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 7:1991;309-345.
16. Hu Z., Prasad Yv.R., Tawa R., Konishi T., Ishida M., Shibata N., Takada K. Diethyl ether fraction of Labrasol having a stronger absorption enhancing effect on gentamicin than Labrasol itself. Int. J. Pharm. 234:2002;223-235.
17. Kajita M., Morishita M., Takayama K., Chiba Y., Tokiwa S., Nagai T. Enhanced enteral bioavailability of vancomycin using water-in-oil-in-water multiple emulsion incorporating highly purified unsaturated fatty acid. J. Pharm. Sci. 89:2000;1243-1252.
18. Fell J.T. Targeting of drugs and delivery systems to specific sites in the gastrointestinal tract. J. Anat. 189:1996;517-519.
19. Ashford M., Fell J.T. Targeting drugs to the colon: delivery systems for oral administration. J. Drug Targeting. 2:1994;241-257.
20. Berry M.K., Russo A., Wishart J.M., Tonkin A., Horowitz M., Jones K.L. Effect of solid meal on gastric emptying of, and glycemic and cardiovascular responses to, liquid glucose in older subjects. Am. J. Physiol. Gastrointest. Liver Physiol. 284:2003;G655-G662.
21. Chen C.P., Chen C.Y., Lu C.L., Chang F.Y., Lee S.D., Chu L.S., Liu R.S., Wu H.C. Infrared spectrometry based 13C-octanoic acid breath test in measuring human solid gastric emptying. J. Gastroenterol. Hepatol. 18:2003;41-46.
22. Gumurdulu Y., Yapar Z., Canataroglu A., Serin E., Gumurdulu D., Kibar M., Colakoglu S. Gastric emptying time and the effect of cisapride in cirrhotic patients with autonomic neuropathy. J. Clin. Gastroenterol. 36:2003;175-178.
23. Guarner F., Malagelada J.R. Gut flora in health and disease. Lancet. 361:2003;512-519.
24. Sinha V.R., Kumria R. Polysaccharides in colon-specific drug delivery. Int. J. Pharm. 224:2001;19-38.
25. Raghavan C.V., Muthulingam C., Jenita J.A., Ravi T.K. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem. Pharm. Bull. (Tokyo). 50:2002;892-895.
26. El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int. J. Pharm. 232:2002;199-211.
27. Rubinstein A., Nakar D., Sintov A. Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharm. Res. 9:1992;276-278.
28. Wong J.W., Yuen K.H. Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins. Int. J. Pharm. 227:2001;177-185.
29. Yano H., Hirayama F., Kamada M., Arima H., Uekama K. Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J. Control. Release. 79:2002;103-112.
30. Pang Y.N., Zhang Y., Zhang Z.R. Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting. World J. Gastroenterol. 8:2002;913-917.
31. Sugahara S., Kajiki M., Kuriyama H., Kobayashi T.R. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol. Pharm. Bull. 25:2002;632-641.
32. Krishnaiah Y.S., Satyanarayana V., Dinesh Kumar B., Karthikeyan R.S., Bhaskar P. In vivo evaluation of guargum-based colon targeted oral drug delivery systems of celecoxib in human volunteers. Eur. J. Drug Metab. Pharmacokinet. 27:2002;273-280.
33. Krishnaiah Y.S., Satyanarayana V., Dinesh Kumar B., Karthikeyan R.S. In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur. J. Pharm. Sci. 16:2002;185-192.
34. Van den Mooter G., Vervoort L., Kinget R. Characterization of methacrylated inulin hydrogels designed for colon targeting: in vitro release of BSA. Pharm. Res. 20:2003;303-307.
35. Wiwattanapatapee R., Lomlim L., Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J. Control. Release. 88:2003;1-9.
36. Marvola M., Nykanen P., Rautio S., Isonen N., Autere A. Enteric polymers as binders and coating materials in multiple-unit site-specific drug delivery systems. Eur. J. Pharm. Sci. 7:1999;259-267.
37. Nykanen P., Lempaa S., Aaltonen M.L., Jurjenson H., Veski P., Marvola M. Citric acid as excipient in multiple-unit enteric-coated tablets for targeting drugs on the colon. Int. J. Pharm. 229:2001;155-162.
38. Sinha V.R., Kumria R. Binders for colon-specific drug delivery: an in vitro evaluation. Int. J. Pharm. 249:2002;23-31.
39. Khan M.Z., Stedul H.P., Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers: II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations. Drug Dev. Ind. Pharm. 26:2000;549-554.
40. Minko T., Dharap S.S., Pakunlu R.I., Colaizzi J.L. Advanced drug delivery systems in cancer chemotherapy. Dis. Manage. Clin. Outcomes. 3:2001;48-54.
41. Kopecek J., Kopeckova P., Minko T., Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:2000;61-81.
42. Lu Z.R., Shiah J.G., Sakuma S., Kopeckova P., Kopecek J. Design of novel bioconjugates for targeted drug delivery. J. Control. Release. 78:2002;165-173.
43. Zeisig R., Ress A., Fichtner I., Walther W. Lipoplexes with alkylphospholipid as new helper lipid for efficient in vitro and in vivo gene transfer in tumor therapy. Cancer Gene Ther. 10:2003;302-311.
44. Devane J., Mulligan S., Martin M. Distal ileum and colon: targeted sites for 5-ASA release. Eur. J. Drug Metab. Pharmacokinet. 3:1991;300-303.
45. Folkes L.K., Greco O., Dachs G.U., Stratford M.R., Wardman P. 5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy. Biochem. Pharmacol. 63:2002;265-272.
46. Perillo N.L., Marcus M.E., Baum L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. 76:1998;402-412.
47. Sihorkar V., Vyas S.P. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J. Pharm. Pharmaceut. Sci. 4:2001;138-158.
48. Lotz M.M., Andrews C.W., Korzelius C.A., Lee E.C., Steele G.D., Clarke A., Mercurio A.M. Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc. Natl. Acad. Sci. USA. 90:1993;3466-3470.
49. Ohannesian D.W., Lotan D., Thomas P., Jessup J.M., Fukuda M., Gabius H.J., Lotan R. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res. 55:1995;2191-2199.
50. Schoeppner H.L., Raz A., Ho S.B., Bresalier R.S. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer. 75:1995;2818-2826.
51. Nagy N., Bronckart Y., Camby I., Legendre H., Lahm H., Kaltner H., Hadari Y., Van Ham P., Yeaton P., Pector J.C., Zick Y., Salmon I., Danguy A., Kiss R., Gabius H.J. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut. 50:2002;392-401.
52. Gabius H.J. Glycohistochemistry: the why and how of detection and localization of endogenous lectins. Anat. Histol. Embryol. 30:2001;3-31.
53. Wadhwa M.S., Rice K.G. Receptor mediated glycotargeting. J. Drug Targeting. 3:1995;111-127.
54. Dudas S.P., Yunker C.K., Sternberg L.R., Byrd J.C., Bresalier R.S. Expression of human intestinal mucin is modulated by the beta-galactoside binding protein galectin-3 in colon cancer. Gastroenterology. 123:2002;817-826.
55. Wan M.X., Riaz A.A., Schramm R., Wang Y., Vestweber D., Menger M.D., Thorlacius H. Leukocyte rolling is exclusively mediated by P-selectinin colonic venules. Br. J. Pharmacol. 135:2002;1749-1756.
56. te Velde A.A., van Kooyk Y., Braat H., Hommes D.W., Dellemijn T.A., Slors J.F., van Deventer S.J., Vyth-Dreese F.A. Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur. J. Immunol. 33:2003;143-151.
57. Yamazaki N., Kojima S., Bovin N.V., Andre S., Gabius S., Gabius H.J. Endogenous lectins as targets for drug delivery. Adv. Drug Deliv. Rev. 43:2000;225-244.
58. Remani P., Nair R.A., Sreelekha T.T., Madhavan J., Vijayakumar T., Nair M.K. Altered expression of jack fruit lectin specific glycoconjugates in benign and malignant human colorectum. J. Exp. Clin. Cancer Res. 19:2000;519-523.
59. Wirth M., Hamilton G., Gabor F. Lectin-mediated drug targeting: quantification of binding and internalization of wheat germ agglutinin and Solanum tuberosum lectin using Caco-2 and HT-29 cells. J. Drug Targeting. 6:1998;95-104.
60. Wirth M., Fuchs A., Wolf M., Ertl B., Gabor F. Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells. Pharm. Res. 15:1998;1031-1037.
61. Wirth M., Kneuer C., Lehr C.M., Gabor F. Lectin-mediated drug delivery: discrimination between cytoadhesion and cytoinvasion and evidence for lysosomal accumulation of wheat germ agglutinin in the Caco-2 model. J. Drug Targeting. 10:2002;439-448.
62. Wirth M., Gerhardt K., Wurm C., Gabor F. Lectin-mediated drug delivery: influence of mucin on cytoadhesion of plant lectins in vitro. J. Control. Release. 79:2002;183-191.
63. Gabor F., Schwarzbauer A., Wirth M. Lectin-mediated drug delivery: binding and uptake of BSA-WGA conjugates using the Caco-2 model. Int. J. Pharm. 237:2002;227-239.
64. Bovin N.V. Polyacrylamide-based glycoconjugates as tools in glycobiology. Glycoconjug. J. 15:1998;431-446.
65. Bovin N.V. Neoglycoconjugates: trade and art. Biochem. Soc. Symp. 69:2002;143-160.
66. Mislovicova D., Masarova J., Svitel J., Mendichi R., Soltes L., Gemeiner P., Danielsson B. Neoglycoconjugates of mannan with bovine serum albumin and their interaction with lectin concanavalin A. Bioconjug. Chem. 13:2002;136-142.
67. Becker B., Furneaux R.H., Reck F., Zubkov O.A. A simple synthesis of 8-(methoxycarbonyl)octyl 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D- mannopyranoside and derivatives and their use in the preparation of neoglycoconjugates. Carbohydr. Res. 315:1999;148-158.
68. Muller-Loennies S., Grimmecke D., Brade L., Lindner B., Kosma P., Brade H.J. A novel strategy for the synthesis of neoglycoconjugates from deacylated deep rough lipopolysaccharides. Endotoxin Res. 8:2002;295-305.
69. Turnbull W.B., Stoddart J.F. Design and synthesis of glycodendrimers. J. Biotechnol. 90:2002;231-255.
70. Singh M., Kisoon N., Ariatti M. Receptor-mediated gene delivery to HepG2 cells by ternary assemblies containing cationic liposomes and cationized asialoorosomucoid. Drug Deliv. 8:2001;29-34.
71. Russell-Jones G.I., Veitch H., Arthur L. Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int. J. Pharm. 190:1999;165-174.
72. Wroblewski S., Rihova B., Rossmann P., Hudcovicz T., Rehakova Z., Kopeckova P., Kopecek J. The influence of a colonic microbiota on HPMA copolymer lectin conjugates binding in rodent intestine. J. Drug Targeting. 9:2001;85-94.
73. Ertl B., Heigl F., Wirth M., Gabor F. Lectin-mediated bioadhesion: preparation, stability and caco-2 binding of wheat germ agglutinin- functionalized poly(D,L-lactic-co-glycolic acid)-microspheres. J. Drug Targeting. 8:2000;173-184.
74. Remmelink M., Darro F., Decaestecker C., De Decker R., Bovin N.V., Gebhart M., Kaltner H., Gabius H.J., Kiss R., Salmon I., Danguy A. In vitro influence of lectins and neoglycoconjugates on the growth of three human sarcoma cell lines. J. Cancer Res. Clin. Oncol. 125:1999;275-285.
75. Hittelet A., Legendre H., Nagy N., Bronckart Y., Pector J.C., Salmon I., Yeaton P., Gabius H.J., Kiss R., Camby I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer. 103:2003;370-379.
76. Kayser K., Hauck E., Andre S., Bovin N.V., Kaltner H., Banach L., Lancaster E., Gabius H.J. Expression of endogenous lectins (galectins, receptors for ABH-epitopes) and the MIB-1 antigen in esophageal carcinomas and their syntactic structure analysis in relation to post-surgical tumor stage and lymph node involvement. Anticancer Res. 21:2001;1439-1444.
77. Kayser K., Zink S., Andre S., Schuring M.P., Hecker E., Klar E., Bovin N.V., Kaltner H., Gabius H.J. Primary colorectal carcinomas and their intrapulmonary metastases: clinical, glyco-, immuno- and lectin histochemical, nuclear and syntactic structure analysis with emphasis on correlation with period of occurrence of metastases and survival. APMIS. 110:2002;435-446.
78. Lotan R., Matsushita Y., Ohannesian D., Carralero D., Ota D.M., Cleary K.R., Nicolson G.L., Irimura T. Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. Carbohydr. Res. 213:1991;47-57.
79. Ohannesian D.W., Lotan D., Lotan R. Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res. 54:1994;5992-6000.
80. Meichenin M., Rocher J., Galanina O., Bovin N., Nifantev N., Sherman A., Cassagnau E., Heymann M.F., Bara J., Fraser R.H., Le Pendu J. Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation. Cancer Res. 60:2000;5499-5507.
81. Galanina O., Hallouin F., Goupille C., Bovin N., Le Pendu J. Detection of a potential receptor for the H-blood-group antigen on rat colon carcinoma cells and normal tissues. Int. J. Cancer. 76:1998;136-140.
82. David A., Kopeckova P., Kopecek J., Rubinstein A. The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl) methacrylamide copolymers by human colon adenocarcinoma cells. Pharm. Res. 19:2002;1114-1122.
83. Luo Y., Prestwich G.D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem. 10:1999;755-763.
84. Luo Y., Bernshaw N.J., Lu Z.R., Kopecek J., Prestwich G.D. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm. Res. 19:2002;396-402.
85. Ma Y., Uemura K., Oka S., Kozutsumi Y., Kawasaki N., Kawasaki T. Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: mannan-binding proteindependent cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA. 96:1999;371-375.
86. Sato T., Sunamoto J., Ishii N., Koji T. Polysaccharide-anchored immunoliposomes bearing anti-CEA Fab' fragment and their internalization by CEA-producing tumor cells. J. Bioact. Compat. Polym. 3:1998;196-204.
87. Dharap S.S., Minko T. Targeted proapoptotic LHRH-BH3 peptide. Pharm. Res. 20:2003;889-896.
88. Minko T., Kopeckova P., Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer. 86:2000;108-117.
89. Minko T., Dharap S.S., Fabbricatore A.T., Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense. Cancer Detect. Prev. 27:2003;194-202.
90. Pakunlu R.I., Cook T.J., Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm. Res. 20:2003;351-359.
91. Minko T. Enhancing the efficacy of anticancer drugs using complex multicomponent advanced drug delivery systems. Business Briefing: Future Drug Discov. 12:2001;134-136.
92. Gross A., McDonnell J.M., Korsmeyer S. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1999;1899-1911.
93. Reed J. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:1999;2941-2953.
94. Abate-Shen C., Shen M.M. Molecular genetics of prostate cancer. Genes Dev. 14:2000;2410-2434.
95. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
96. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis. 21:2000;485-495.
97. Mano Y., Kikuchi Y., Yamamoto K., Kita T., Hirata J., Tode T., Ishii K., Nagata I. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur. J. Cancer. 35:1999;1214-1219.
98. Cosulich S.C., Worrall V., Hedge P.J., Green S., Clarke P.R. Regulation of apoptosis by BH3 domains in a cell-free system. Curr. Biol. 7:1997;913-920.
99. Johnson A.L. Editorial: Mcl-1 - just another antiapoptotic BCL-2 homolog? Endocrinology. 140:1999;5465-5467.
100. Lutz R.J. Role of the BH3 (BCL-2 homology 3) domain in the regulation of apoptosis and BCL-2-related proteins. Biochem. Sci. Trans. 28:(Part 2):2000;51-56.
101. Holinger E., Chittenden T., Lutz R.J. Bak BH3 peptides antagonize BCL-XL functions and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem. 274:1999;13298-13304.